Pharmacological effects of TAK-828F

an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease

Keiko Igaki, Yoshiki Nakamura, Masayuki Tanaka, Shinta Mizuno, Yusuke Yoshimatsu, Yusaku Komoike, Keiko Uga, Akira Shibata, Hisashi Imaichi, Satou Takayuki, Yoshimasa Ishimura, Masashi Yamasaki, Takanori Kanai, Yasuhiro Tsukimi, Noboru Tsuchimori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective and design: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. Methods and results: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ −/− mice. TAK-828F strongly inhibited IL-17 gene expression with IC 50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. Conclusions: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.

Original languageEnglish
Pages (from-to)493-509
Number of pages17
JournalInflammation Research
Volume68
Issue number6
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Colitis
Inflammatory Bowel Diseases
Blood Cells
Monoclonal Antibodies
Pharmacology
Interleukin-17
Treatment Failure
Interleukin-23
Gene Expression
Th17 Cells
Lymphocyte Count
Intestinal Mucosa
Interleukin-12
Antibody Formation
Virulence
Cell Count
T-Lymphocytes
Therapeutics
Population

Keywords

  • IL-23/Th17 pathway
  • Inflammatory bowel disease
  • Mouse colitis model
  • RORγt inverse agonist
  • TAK-828F

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Pharmacological effects of TAK-828F : an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease. / Igaki, Keiko; Nakamura, Yoshiki; Tanaka, Masayuki; Mizuno, Shinta; Yoshimatsu, Yusuke; Komoike, Yusaku; Uga, Keiko; Shibata, Akira; Imaichi, Hisashi; Takayuki, Satou; Ishimura, Yoshimasa; Yamasaki, Masashi; Kanai, Takanori; Tsukimi, Yasuhiro; Tsuchimori, Noboru.

In: Inflammation Research, Vol. 68, No. 6, 01.06.2019, p. 493-509.

Research output: Contribution to journalArticle

Igaki, K, Nakamura, Y, Tanaka, M, Mizuno, S, Yoshimatsu, Y, Komoike, Y, Uga, K, Shibata, A, Imaichi, H, Takayuki, S, Ishimura, Y, Yamasaki, M, Kanai, T, Tsukimi, Y & Tsuchimori, N 2019, 'Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease', Inflammation Research, vol. 68, no. 6, pp. 493-509. https://doi.org/10.1007/s00011-019-01234-y
Igaki, Keiko ; Nakamura, Yoshiki ; Tanaka, Masayuki ; Mizuno, Shinta ; Yoshimatsu, Yusuke ; Komoike, Yusaku ; Uga, Keiko ; Shibata, Akira ; Imaichi, Hisashi ; Takayuki, Satou ; Ishimura, Yoshimasa ; Yamasaki, Masashi ; Kanai, Takanori ; Tsukimi, Yasuhiro ; Tsuchimori, Noboru. / Pharmacological effects of TAK-828F : an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease. In: Inflammation Research. 2019 ; Vol. 68, No. 6. pp. 493-509.
@article{e10882d3838b47b280313871043dcc55,
title = "Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease",
abstract = "Objective and design: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. Methods and results: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ −/− mice. TAK-828F strongly inhibited IL-17 gene expression with IC 50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. Conclusions: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.",
keywords = "IL-23/Th17 pathway, Inflammatory bowel disease, Mouse colitis model, RORγt inverse agonist, TAK-828F",
author = "Keiko Igaki and Yoshiki Nakamura and Masayuki Tanaka and Shinta Mizuno and Yusuke Yoshimatsu and Yusaku Komoike and Keiko Uga and Akira Shibata and Hisashi Imaichi and Satou Takayuki and Yoshimasa Ishimura and Masashi Yamasaki and Takanori Kanai and Yasuhiro Tsukimi and Noboru Tsuchimori",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s00011-019-01234-y",
language = "English",
volume = "68",
pages = "493--509",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "6",

}

TY - JOUR

T1 - Pharmacological effects of TAK-828F

T2 - an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease

AU - Igaki, Keiko

AU - Nakamura, Yoshiki

AU - Tanaka, Masayuki

AU - Mizuno, Shinta

AU - Yoshimatsu, Yusuke

AU - Komoike, Yusaku

AU - Uga, Keiko

AU - Shibata, Akira

AU - Imaichi, Hisashi

AU - Takayuki, Satou

AU - Ishimura, Yoshimasa

AU - Yamasaki, Masashi

AU - Kanai, Takanori

AU - Tsukimi, Yasuhiro

AU - Tsuchimori, Noboru

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Objective and design: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. Methods and results: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ −/− mice. TAK-828F strongly inhibited IL-17 gene expression with IC 50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. Conclusions: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.

AB - Objective and design: To evaluate the potency of RORγt blockade for treatment of Inflammatory Bowel Disease (IBD), the efficacy of TAK-828F, a novel RORγt inverse agonist, in anti-TNF-α mAb non-responsive mouse colitis model and effect of TAK-828F on IL-17 production in peripheral mononuclear blood cells (PBMCs) of anti-TNF-α naive and treatment-failure patients of IBD was investigated. Methods and results: The colitis model showed Th17-dependent pathogenicity and response to anti-IL-12/23p40 monoclonal antibody (mAb), but no response to anti-TNF-α mAb. In the model, TAK-828F, at oral dosages of 1 and 3 mg/kg, inhibited progression of colitis and reduced the immune reaction that characterize Th17 cells. Anti-IL-17A mAb showed neither efficacy nor change in the T cell population and colonic gene expression in the model. In the normal mouse, a 4-week treatment of TAK-828F at 30 mg/kg did not severely reduce lymphocyte cell counts in peripheral and intestinal mucosa, which was observed in RORγ −/− mice. TAK-828F strongly inhibited IL-17 gene expression with IC 50 values from 21.4 to 34.4 nmol/L in PBMCs from anti-TNF mAb naive and treatment-failure patients of IBD. Conclusions: These results indicate that RORγt blockade would provide an effective approach for treating refractory patients with IBD by blocking IL-23/Th17 pathway.

KW - IL-23/Th17 pathway

KW - Inflammatory bowel disease

KW - Mouse colitis model

KW - RORγt inverse agonist

KW - TAK-828F

UR - http://www.scopus.com/inward/record.url?scp=85065715855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065715855&partnerID=8YFLogxK

U2 - 10.1007/s00011-019-01234-y

DO - 10.1007/s00011-019-01234-y

M3 - Article

VL - 68

SP - 493

EP - 509

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 6

ER -